

NAD+ — Certificates of Analysis

Every batch we have tested for this product, newest first.

Match the strength on your vial to the rows below and turn to that page.

PAGE	STRENGTH	BATCH / LOT
2–3	21mg	8/13/2026 · 1000mg · Lot IWR-081026NAD1K
4–5	89mg, 500mg	8/13/2026 · 500mg · Lot IWR-081026NAD500
6–12	20mg, 51mg, 490mg, 500mg	8/21/2026
13–16	497mg, 500mg, 990mg	2/22/2026



Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com |
summitbioanalytics.com

TESTED FOR

Iron Within Research

SAMPLE

NAD+ — 1000 mg

PASS

BATCH #

IWR-081026NAD1K

PURITY

99.34%

MASS

1087.21 mg

IDENTITY

Confirmed

COA #:

SBA-26-0089

Method:

Full QC Panel

Lot Number:

IWR-081026NAD1K

Analysis Date:

2026-08-13

Labeled Content:

1000 mg

Date Received:

2026-08-10

Appearance:

White lyophilized powder, intact seal

Vial Cap:

Clear #A4A2A7



SCAN TO VERIFY



Identity



Purity



Endotoxins



Fentanyl Free

Test	Specification	Result
Identity	NAD+	Confirmed
Purity (HPLC)	>= 98.0%	99.34%
Content (per vial)	Report only	1087.21 mg/vial
Fentanyl Screen (LC-MS/MS)	Not detected	Not detected
Endotoxins (LAL)	Report Result	0.03 EU/mL
Sterility Screen (rapid PCR)	No growth	No growth
Heavy Metals (ICP-MS)	ICH Q3D limits	All analytes within limits

Qualitative and quantitative chemical analysis by RP-HPLC with UV detection; identity confirmed by LC-MS. Fentanyl screening by targeted LC-MS/MS. Sterility by rapid nucleic-acid amplification — a screening method, not compendial sterility per USP <71>. Full methodology available on request.

Kasey Malganus

Kasey Malganus

Lab Director

2026-08-13

COA #:

SBA-26-0089

Access Code:

AXJLGBQJ

Analyst:

A. Grinder

Verify:

summitbioanalytics.com/verify

Issued:

2026-08-13

Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com

This certificate relates only to the item tested, as received. Research use only — not for human or veterinary use. A not-detected screening result describes this sample only and is not a statement about any other unit or lot.



Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com |
summitbioanalytics.com

TESTED FOR

Iron Within Research

SAMPLE

NAD+ — 500 mg

PASS

BATCH #

IWR-
081026NAD500

PURITY

99.42%

MASS

507.89 mg

IDENTITY

Confirmed

COA #:

SBA-26-0090

Method:

Full QC Panel

Lot Number:

IWR-081026NAD500

Analysis Date:

2026-08-13

Labeled Content:

500 mg

Date Received:

2026-08-10

Appearance:

White lyophilized
powder, intact seal

Vial Cap:

 Copper #C5815A



SCAN TO VERIFY



Identity



Purity



Endotoxins



Fentanyl Free

Test	Specification	Result
Identity	NAD+	Confirmed
Purity (HPLC)	>= 98.0%	99.42%
Content (per vial)	Report only	507.89 mg/vial
Fentanyl Screen (LC-MS/MS)	Not detected	Not detected
Endotoxins (LAL)	Report Result	0.01 EU/mL
Sterility Screen (rapid PCR)	No growth	No growth
Heavy Metals (ICP-MS)	ICH Q3D limits	All analytes within limits

Qualitative and quantitative chemical analysis by RP-HPLC with UV detection; identity confirmed by LC-MS. Fentanyl screening by targeted LC-MS/MS. Sterility by rapid nucleic-acid amplification — a screening method, not compendial sterility per USP <71>. Full methodology available on request.

Kasey Malganus

Kasey Malganus

Lab Director

2026-08-13

COA #:

SBA-26-0090

Access Code:

7JB9M835

Analyst:

A. Grinder

Verify:

summitbioanalytics.com/verify

Issued:

2026-08-13

Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com

This certificate relates only to the item tested, as received. Research use only — not for human or veterinary use. A not-detected screening result describes this sample only and is not a statement about any other unit or lot.

Lot Number: **IWR-6384965-P**
 Client Name: **Iron Within Research**
 Identity: **www.ironwithinresearch.com**

Received Date: **06/29/2026**
 Analysis Conducted: **06/24/2026**
 Searchable via: **horizonanalytical.com**


Compound:	NAD ⁺
Lot:	IWR-6384965-P
Appearance:	White Lyophilized Powder

CAS:	53-84-9
Formula:	C ₂₁ H ₂₇ N ₇ O ₁₄ P ₂
Mol Weight:	~663.43 g/mol


Pubchem CID: 925

Qualitative and Quantitative chemical analysis by Ultra High Performance Liquid Chromatography with Mass Spectrometry

	Specification	Result	Scan to Validate:
Compound Test:	NAD ⁺	NAD ⁺	
Quantity:	500mg	490mg	
Purity:	>98%	99.49%	



UPLC



MS

Aleksey Yevtodiyyenko PhD
Research and Formulation Chemist




This purity analysis was conducted using UPLC/MS under standard laboratory conditions, following validated analytical protocols to ensure accurate and reliable results. This analysis is intended for informational and research applications.


Lot Number: IWR-6384965-P
Client Name: Iron Within Research
Identity: www.ironwithinresearch.com

Received Date: 06/29/2026
Analysis Conducted: 06/24/2026
Searchable via: horizonanalytical.com

NAD⁺ (500mg) • Pubchem CID: 925
Ultra High Performance Liquid Chromatography (UPLC)



Mass Spectrometry (MS)



Lot Number: IWR-6384965-E
Client Name: Iron Within Research
Identity: www.ironwithinresearch.com

Received Date: 06/29/2026
Analysis Conducted: 06/24/2026
Searchable via: horizonanalytical.com

Compound:	NAD+
Lot:	IWR-6384965-E
Appearance:	-

CAS:	53-84-9
Formula:	C ₂₁ H ₂₇ N ₇ O ₁₄ P ₂
Mol Weight:	~663.43 g/mol

Pubchem CID: 925

Endotoxin Test

	Specification	Result	Scan to Validate:
Compound Test:	NAD+	-	
Endotoxin:	-	< 0.05 EU/mL	

Aleksey Yevtodiyenko PhD
Research and Formulation Chemist



This endotoxin analysis was performed under standard laboratory conditions using validated testing methodologies to ensure accurate and reliable results. The analysis is intended for informational and research purposes only.

Contact at: contact@horizonanalytical.comProudly Owned and Operated in the USA 



Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com |
summitbioanalytics.com

TESTED FOR

Iron Within Research

SAMPLE

NAD+ — 1000 mg

PASS

BATCH #

IWR-2607-
NAD1000

PURITY

99.97%

MASS

1009.20 mg

IDENTITY

Confirmed

COA #:

SBA-26-0021

Method:

Full QC Panel

Lot Number:

IWR-2607-NAD1000

Analysis Date:

2026-08-02

Labeled Content:

1000 mg

Date Received:

2026-07-29

Appearance:

Lyophilized powder in
amber glass vial, intact
seal



SCAN TO VERIFY



Identity




Purity



Endotoxins



Fentanyl Free



VIAL CAP

White

#E8E8EA

CLOSURE AS
RECEIVED

Test	Specification	Result
Identity	NAD+	Confirmed
Purity (HPLC)	>= 98.0%	99.97%
Content (gross)	Report only	1009.20 mg
Fentanyl Screen (LC-MS/MS)	Not detected	Not detected

Test	Specification	Result
Endotoxins (LAL)	Report Result	0.09 EU/mL
Sterility Screen (rapid PCR)	No growth	No growth
Heavy Metals (ICP-MS)	ICH Q3D limits	All analytes within limits

Qualitative and quantitative chemical analysis by RP-HPLC with UV detection; identity confirmed by LC-MS. Fentanyl screening by targeted LC-MS/MS. Sterility by rapid nucleic-acid amplification — a screening method, not compendial sterility per USP <71>. Full methodology available on request.

Kasey Malganus

Kasey Malganus
Lab Director
2026-08-02

COA #: SBA-26-0021
Access Code: DA5V25SR
Analyst: R. Whitfield
Verify: summitbioanalytics.com/verify
Issued: 2026-08-02

Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com

This certificate relates only to the item tested, as received. Research use only — not for human or veterinary use. A not-detected screening result describes this sample only and is not a statement about any other unit or lot.



Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com |
summitbioanalytics.com

TESTED FOR

Iron Within Research

SAMPLE

NAD+ — 500 mg

PASS

BATCH #

IWR-2607-
NAD500

PURITY

99.94%

MASS

584.51 mg

IDENTITY

Confirmed

COA #:

SBA-26-0022

Method:

Full QC Panel

Lot Number:

IWR-2607-NAD500

Analysis Date:

2026-08-02

Labeled Content:

500 mg

Date Received:

2026-07-29

Appearance:

Lyophilized powder in
amber glass vial, intact
seal



SCAN TO VERIFY



Identity




Purity



Endotoxins



Fentanyl Free



VIAL CAP

White

#E8E8EA

CLOSURE AS
RECEIVED

Test	Specification	Result
Identity	NAD+	Confirmed
Purity (HPLC)	>= 98.0%	99.94%
Content (gross)	Report only	584.51 mg
Fentanyl Screen (LC-MS/MS)	Not detected	Not detected

Test	Specification	Result
Endotoxins (LAL)	Report Result	0.03 EU/mL
Sterility Screen (rapid PCR)	No growth	No growth
Heavy Metals (ICP-MS)	ICH Q3D limits	All analytes within limits

Qualitative and quantitative chemical analysis by RP-HPLC with UV detection; identity confirmed by LC-MS. Fentanyl screening by targeted LC-MS/MS. Sterility by rapid nucleic-acid amplification — a screening method, not compendial sterility per USP <71>. Full methodology available on request.

Kasey Malganus

Kasey Malganus
Lab Director
2026-08-02

COA #: SBA-26-0022
Access Code: UTCVX48B
Analyst: R. Whitfield
Verify: summitbioanalytics.com/verify
Issued: 2026-08-02

Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com

This certificate relates only to the item tested, as received. Research use only — not for human or veterinary use. A not-detected screening result describes this sample only and is not a statement about any other unit or lot.

Lot Number: **IWR-4407912-P**
 Client Name: **Iron Within Research**
 Identity: **www.ironwithinresearch.com**

Received Date: **04/21/2026**
 Analysis Conducted: **04/16/2026**
 Searchable via: **horizonanalytical.com**


Compound:	NAD+
Lot:	IWR-4407912-P
Appearance:	White Lyophilized Powder

CAS:	53-84-9
Formula:	C ₂₁ H ₂₇ N ₇ O ₁₄ P ₂
Mol Weight:	~663.43 g/mol


Pubchem CID: 925

Qualitative and Quantitative chemical analysis by Ultra High Performance Liquid Chromatography with Mass Spectrometry

	Specification	Result	Scan to Validate:
Compound Test:	NAD+	NAD+	
Quantity:	1000mg	990mg	
Purity:	>98%	99.56%	



UPLC



MS

Aleksey Yevtodiyyenko PhD
Research and Formulation Chemist




This purity analysis was conducted using UPLC/MS under standard laboratory conditions, following validated analytical protocols to ensure accurate and reliable results. This analysis is intended for informational and research applications.


Lot Number: IWR-4407912-P
 Client Name: Iron Within Research
 Identity: www.ironwithinresearch.com

Received Date: 04/21/2026
 Analysis Conducted: 04/16/2026
 Searchable via: horizonanalytical.com

NAD⁺ (1000mg) • Pubchem CID: 925
 Ultra High Performance Liquid Chromatography (UPLC)



Mass Spectrometry (MS)



Lot Number: **IWR-6282635-P**
 Client Name: **Iron Within Research**
 Identity: **www.ironwithinresearch.com**

Received Date: **04/21/2026**
 Analysis Conducted: **04/16/2026**
 Searchable via: **horizonanalytical.com**


Compound:	NAD+
Lot:	IWR-6282635-P
Appearance:	White Lyophilized Powder

CAS:	53-84-9
Formula:	C ₂₁ H ₂₇ N ₇ O ₁₄ P ₂
Mol Weight:	~663.43 g/mol


Pubchem CID: 925

Qualitative and Quantitative chemical analysis by Ultra High Performance Liquid Chromatography with Mass Spectrometry

	Specification	Result	Scan to Validate:
Compound Test:	NAD+	NAD+	
Quantity:	500mg	497mg	
Purity:	>98%	99.39%	



UPLC



MS

Aleksey Yevtodiyenko PhD
Research and Formulation Chemist




This purity analysis was conducted using UPLC/MS under standard laboratory conditions, following validated analytical protocols to ensure accurate and reliable results. This analysis is intended for informational and research applications.

Lot Number: IWR-6282635-P
Client Name: Iron Within Research
Identity: www.ironwithinresearch.com

Received Date: 04/21/2026
Analysis Conducted: 04/16/2026
Searchable via: horizonanalytical.com

NAD⁺ (500mg) • Pubchem CID: 925
Ultra High Performance Liquid Chromatography (UPLC)



Mass Spectrometry (MS)

